Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 0.57 |
| ▸ | INSR | P06213 | 4/20 | 0.57 |
| ▸ | ALK | Q9UM73 | 11/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.51 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.51 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24073465 | 1.00 | MET (0.57) | METINSRALKMAPK8MAPK9 | |
| SCHEMBL25834917 | 0.93 | MET (0.58) | METINSRALKMAPK8MAPK9 | |
| SCHEMBL30266648 | 0.93 | MET (0.58) | METINSRALKMAPK8MAPK9 | |
| SCHEMBL24073937 | 0.93 | MET (0.58) | METINSRALKMAPK8MAPK9 | |
| SCHEMBL24073413 | 0.92 | MET (0.60) | METINSRALKPTK2MAP4K1 | |
| SCHEMBL24073933 | 0.92 | MET (0.57) | METINSRALKMAPK8MAPK9 | |
| SCHEMBL30266566 | 0.92 | MET (0.57) | METINSRALKMAPK8MAPK9 | |
| SCHEMBL24073722 | 0.92 | MET (0.57) | METINSRALKMAPK8MAPK9 | |
| SCHEMBL24073717 | 0.91 | MET (0.69) | METINSRALKMAPK8MAPK9 | |
| SCHEMBL24073480 | 0.91 | MET (0.69) | METINSRALKMAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | AXL, FLT3, TYMP | MET 356/4885INSR 1450/4885ALK 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.